Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin

被引：1
|
作者：
Sahin, Mustafa [1 ]
Miskioglu, Mine [2 ]
Inanir, Isil [3 ]
Akar, Hikmet [1 ]
Nese, Nalan [4 ]
Temiz, Peyker [4 ]
Aydogdu, Ismet [2 ]
机构：
[1] Celal Bayar Univ, Fac Med, Dept Internal Med, Manisa, Turkey
[2] Celal Bayar Univ, Fac Med, Dept Hematol, Manisa, Turkey
[3] Celal Bayar Univ, Fac Med, Dept Dermatol, Manisa, Turkey
[4] Celal Bayar Univ, Fac Med, Dept Patol, Manisa, Turkey
来源：
TURKISH JOURNAL OF HEMATOLOGY | 2021年 / 38卷 / 01期
关键词：
Cutaneous anaplastic large cell lymphoma; Brentuximab; Monotherapy; Breast cancer;
D O I：
10.4274/tjh.galenos.2020.2020.0512
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：85 / 87
页数：4
相关论文
共 50 条
  • [1] Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma
    Foyil, Kelley V.
    Bartlett, Nancy L.
    CANCER JOURNAL, 2012, 18 (05): : 450 - 456
  • [2] Disease control with brentuximab vedotin in an aged patient with primary cutaneous anaplastic large-cell lymphoma
    Burgstaller S.
    Thaler J.
    memo - Magazine of European Medical Oncology, 2017, 10 (3) : 170 - 172
  • [3] Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
    Onaka, Takashi
    Kitagawa, Tomoya
    Kawakami, Chika
    Yonezawa, Akihito
    TURKISH JOURNAL OF HEMATOLOGY, 2018, 35 (02) : 135 - 136
  • [4] Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report
    Arroyo-Andres, Jorge
    Agud-Dios, Manuel
    Rubio-Muniz, Carmen A.
    Vico-Alonso, Cristina
    Cortijo-Cascajares, Susana
    Ortiz-Romero, Pablo L.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (07) : E267 - E269
  • [5] FDA Approves Brentuximab Vedotin for Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma
    不详
    ONCOLOGY-NEW YORK, 2011, 25 (10): : 904 - +
  • [6] Brentuximab vedotin in anaplastic large cell lymphoma
    Skarbnik, Alan P. Z.
    Smith, Mitchell R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 633 - 639
  • [7] Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review
    Donato, Eva M.
    Fernandez-Zarzoso, Miguel
    Antonio Hueso, Jose
    de la Rubia, Javier
    ONCOTARGETS AND THERAPY, 2018, 11 : 4583 - 4590
  • [8] Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma
    Chen, Robert
    Allibone, Suzanne
    Bartlett, Nancy L.
    Brice, Pauline
    Chen, Andy
    Pose, Katrina
    Rich, Lynn
    Bonthapally, Vijay
    Garfin, Phillip M.
    Fanale, Michelle
    ONCOTARGETS AND THERAPY, 2016, 9 : 2027 - 2034
  • [9] Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma
    Lai, Chao-Ming
    Horowitz, Sandra
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (04) : 361 - 373
  • [10] Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma
    Alderuccio, Juan Pablo
    Desai, Amrita
    Yepes, Monica M.
    Chapman, Jennifer R.
    Vega, Francisco
    Lossos, Izidore S.
    CLINICAL CASE REPORTS, 2018, 6 (04): : 634 - 637
12345